BlackRock, Inc. 13D and 13G filings for Sangamo Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-07-08 4:32 pm Sale |
2024-06-30 | 13G | Sangamo Therapeutics, Inc. SGMO |
BlackRock Inc. BLK |
4,702,938 2.300% |
-9,392,927 (-66.64%) |
Filing |
| 2024-01-26 11:49 am Sale |
2023-12-31 | 13G | Sangamo Therapeutics, Inc. SGMO |
BlackRock Inc. BLK |
14,095,865 7.900% |
-1,263,576 (-8.23%) |
Filing |
| 2023-01-24 1:56 pm Purchase |
2022-12-31 | 13G | Sangamo Therapeutics, Inc. SGMO |
BlackRock Inc. BLK |
15,359,441 9.400% |
3,696,561 (+31.70%) |
Filing |
| 2022-02-01 5:08 pm Purchase |
2021-12-31 | 13G | Sangamo Therapeutics, Inc. SGMO |
BlackRock Inc. BLK |
11,662,880 8.000% |
2,096,465 (+21.91%) |
Filing |
| 2021-02-01 08:23 am Purchase |
2020-12-31 | 13G | Sangamo Therapeutics, Inc. SGMO |
BlackRock Inc. BLK |
9,566,415 6.800% |
32,144 (+0.34%) |
Filing |